XOMA Corporation (XOMA): Debts to Book Capitalization

This daily price chart for XOMA Royalty (XOMA) shows figures at 1.07. XOMA Royalty (XOMA) operates as a royalty collector, having completely abandoned its own laboratory research. Its strategy relies on outsourcing all R&D and production cycles to external contractors, allowing the company to manage assets with minimal staff. Final income is based on patent ownership, while the company independently controls the financial flows received from pharma behemoths.

XOMA - XOMA Corp Debts to Net Assets over the range 07/04/2022 - 07/25/2026

xoma.com (XOMA) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Quotes XOMA Royalty Corporation|XOMA - Price Target Chart

- market capitalization data:

Market Capitalization XOMA|XOMA - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share XOMA Royalty|XOMA - Book Valuation of Business|Market Cap to Net Assets Ratio xoma.com|XOMA - Aggregate Business Assets

- debt and liquidity data:

Fundamental company analysis:XOMA Corp - XOMA

Core merchandise of XOMA Royalty Corporation

The specifics of XOMA Royalty (XOMA) investments in antibody licensing and R&D platforms are reflected in the debt-to-equity ratio chart, where the current value of 1.07 characterizes the degree of financial leverage. This indicator measures the ratio of total liabilities to equity, allowing for an assessment of the pace at which the credit load is decreasing relative to the market value of specialized scientific assets to determine default risk.

Who XOMA Royalty competes with